Lipocine delays LPCN 2401 POC study, seeks FDA clarity on endpoints

Lipocine Inc.

Received IND clearance for LPCN 2401 as adjunct to GLP-1 therapy.
Seeking regulatory clarity on POC study endpoints, including functional loss.
POC study on hold pending FDA feedback; corporate presentation updated.
No timeline provided for resolution; development path uncertain.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.